MAGEA10 and cancer: Cellular and humoral immune responses specific for cancer/testis antigens (CTAs), and, in particular, MAGE-A10, have frequently been observed in patients with tumors of different histological origin (e.g., [14,15,16]) and were not reported to be associated with clinical symptoms suggesting ongoing autoimmune reactions targeting healthy tissues.